Have you recently been diagnosed with higher-risk myelodysplastic syndrome (MDS) and been advised to receive a medication called azacitidine?

Now enrolling: the STIMULUS-MDS2 clinical trial, a clinical research study evaluating the immuno-myeloid therapy sabatolimab in combination with azacitidine for patients with higher-risk MDS or chronic myelomonocytic leukemia-2 (CMML-2).

Participants must meet the following criteria:

• 18 years of age or older
• Diagnosed with intermediate-, high-, or very high-risk MDS or CMML-2
• Have not received prior treatment
• Have not had a prior organ or stem cell transplant
• Are not eligible for a stem cell transplant or intensive chemotherapy

If you are interested in participating and think you meet these criteria, please contact your doctor to discuss your eligibility for the STIMULUS-MDS2 clinical trial.

For more information, visit ClinicalTrials.gov/ct2/show/NCT04266301 or search “STIMULUS-MDS2” in any internet browser.

Sabatolimab (MBG453) is an investigational compound. Efficacy and safety have not been established. There is no guarantee that sabatolimab will become commercially available.